- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02375880
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In Part A, escalating doses of DKN-01 will be administered to different cohorts of patients to evaluate safety and dose limiting toxicities (DLTs) and to establish the maximum tolerated dose of DKN-01 when administered in combination with gemcitabine and cisplatin.
Part B is an expansion cohort in which patients are treated at the MTD of DKN-01 (or highest dose tested if the MTD is not defined) to further characterize safety, tolerability, pharmacokinetics and efficacy within the defined patient population.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
Boston, Massachusetts, United States, 02214
- Massachusetts General Hospital
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Cleveland, Ohio, United States, 44106
- University Hospitals, Case Medical Center
-
-
Texas
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center at San Antonio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient has carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder.
- Patient must have sufficient tumor tissue available for submission.
- For patients who have received prior cryotherapy, radiofrequency ablation, radioembolization, ethanol injection, transarterial chemoembolization (TACE) or photodynamic therapy, at least 28 days must have elapsed since that therapy, and lesions that have not been treated with local therapy must be present and measurable.
- Patients may have received prior adjuvant chemotherapy with gemcitabine with or without cisplatin, as long as 6 months have elapsed since last treatment.
- Patients must have one or more tumors measurable on radiographic imaging as defined by RECIST.
- ECOG PS of 0 or 1. Patients with an ECOG PS of 2 may be entered upon review and approval of the medical monitor.
- Estimated life expectancy of at least 3 months.
- Disease-free of active second/secondary or prior malignancies for ≥ 2 years with the exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast.
- Adequate hematological, renal, hepatic and coagulation laboratory test results.
- Women of child bearing potential and men must agree to use adequate contraception during the study and for 6 months after their last dose of study drug.
- Available for the duration of the study and are willing to follow study-specific procedures.
- Provide written informed consent
Exclusion Criteria:
- New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, or unstable arrhythmia.
- Have Fridericia-corrected QT interval (QTcF) > 470 msec (female) or > 450 (male), or history of congenital long QT syndrome.
- Active, uncontrolled bacterial, viral, or fungal infections.
- Known to be human immunodeficiency virus (HIV) positive or has untreated, active hepatitis B.
- History of major organ transplant.
- History of an autologous/allogenic bone marrow transplant.
- Serious nonmalignant disease.
- Pregnant or nursing.
- History of osteonecrosis of the hip or have evidence of structural bone abnormalities in the proximal femur on MRI scan that are symptomatic and clinically significant.
- Symptomatic central nervous system (CNS) malignancy or metastasis.
- Clinically significant peripheral neuropathy
- Known osteoblastic bony metastasis.
- Treatment with surgery or chemotherapy within 21 days prior to study entry or radiation within 14 days of study entry.
- Previously treated with an anti-Dkk-1 therapy.
- Other exclusions apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 150 mg DKN-01 Part A
Patients will receive 150 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
|
Administration by intravenous (IV) infusion.
Other Names:
Administered by IV infusion.
Other Names:
Administered by IV infusion
Other Names:
|
EXPERIMENTAL: 300 mg DKN-01 Part A
Patients will receive 300 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
|
Administration by intravenous (IV) infusion.
Other Names:
Administered by IV infusion.
Other Names:
Administered by IV infusion
Other Names:
|
EXPERIMENTAL: MTD mg DKN-01 Part B
Patients are treated at the maximum tolerated dose (MTD) of DKN-01 (or highest dose tested in Part A if the MTD is not defined) followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
|
Administration by intravenous (IV) infusion.
Other Names:
Administered by IV infusion.
Other Names:
Administered by IV infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose and dose-limiting toxicities as determined in Part A.
Time Frame: End of Cycle 1 (Day 21)
|
Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 4.03).
|
End of Cycle 1 (Day 21)
|
Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events.
Time Frame: Parts A and B: at a minimum Days 1, 8, 15 of each treatment cycle.
|
Parts A and B: at a minimum Days 1, 8, 15 of each treatment cycle.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics - AUC
Time Frame: Cycle 1 - Days 1 and 8, Cycle 2 - Day 1
|
Plasma levels will be measured during the treatment period.
|
Cycle 1 - Days 1 and 8, Cycle 2 - Day 1
|
Pharmacokinetics - Cmax
Time Frame: Cycle 1 - Days 1 and 8, Cycle 2 - Day 1
|
Plasma levels will be measured during the treatment period.
|
Cycle 1 - Days 1 and 8, Cycle 2 - Day 1
|
Pharmacokinetics - Tmax
Time Frame: Cycle 1 - Days 1 and 8, Cycle 2 - Day 1
|
Plasma levels will be measured during the treatment period.
|
Cycle 1 - Days 1 and 8, Cycle 2 - Day 1
|
Efficacy - Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1)
Time Frame: At baseline, prior to the start of Cycle 3, and every 2 cycles thereafter until disease progression or death
|
Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1).
|
At baseline, prior to the start of Cycle 3, and every 2 cycles thereafter until disease progression or death
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Biliary Tract Diseases
- Bile Duct Diseases
- Biliary Tract Neoplasms
- Carcinoma
- Cholangiocarcinoma
- Bile Duct Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
- Cisplatin
Other Study ID Numbers
- DEK-DKK1-P103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholangiocarcinoma
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic CholangiocarcinomaUnited States
-
RedHill Biopharma LimitedCompletedCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, IntrahepaticUnited States
-
RedHill Biopharma LimitedAvailableCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); CelgeneActive, not recruitingResectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8United States
-
National Cancer Institute (NCI)CompletedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable CholangiocarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)WithdrawnStage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8United States
-
AIO-Studien-gGmbHServierCompletedCholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma AdvancedGermany
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma | Advanced CholangiocarcinomaUnited States
-
University of Kansas Medical CenterNational Cancer Institute (NCI)RecruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent CholangiocarcinomaUnited States
Clinical Trials on DKN-01
-
Leap Therapeutics, Inc.AvailableGastric Cancer | Ovarian Cancer | Gastric Adenocarcinoma | Carcinosarcoma | Endometrial Cancer | Adenocarcinoma of the Gastroesophageal Junction | GastroEsophageal Cancer | Uterine Cancer | Esophageal Neoplasm | Squamous Cell CarcinomaUnited States
-
Leap Therapeutics, Inc.CompletedMultiple Myeloma | Non-Small Cell Lung Cancer | Solid TumorsUnited States
-
Johannes Gutenberg University MainzLeap Therapeutics, Inc.Unknown
-
Leap Therapeutics, Inc.CompletedOvarian Cancer | Carcinosarcoma | Endometrial Cancer | Uterine CancerUnited States
-
Leap Therapeutics, Inc.Merck Sharp & Dohme LLCCompletedEsophageal Neoplasms | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma | Gastroesophageal CancerUnited States
-
NYU Langone HealthLeap Therapeutics, Inc.Terminated
-
Royal Marsden NHS Foundation TrustRecruitingMetastatic Gastric Cancer | Metastatic Esophageal CancerUnited Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Leap Therapeutics,...Recruiting
-
Massachusetts General HospitalBristol-Myers Squibb; Leap Therapeutics, Inc.TerminatedBiliary Tract CancerUnited States
-
Leap Therapeutics, Inc.BeiGeneActive, not recruitingGastric Cancer | Gastric Adenocarcinoma | GastroEsophageal CancerUnited States, Korea, Republic of, Germany